The full dataset from Amgen Inc.'s GLAGOV imaging study shows a solid magnitude of plaque regression associated with the PCSK9 inhibitor Repatha and presents no red flags ahead of the release of outcomes data, which are expected in early 2017.
GLAGOV is an intravascular ultrasound study examining the use of a monthly Repatha injection on top of background statin therapy...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)